Tricaprilin

Phase 3Small molecule

CCerecin

Tricaprilin is one of 105 small molecule programs targeting Alzheimer disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer DiseaseActive, not recruiting

Memory ImpairmentActive, not recruiting

MigraineActive, not recruiting

Infantile SpasmsActive, not recruiting

Alzheimer DiseasePhase 3

Active, not recruiting

Memory ImpairmentPhase 2

Active, not recruiting

MigrainePhase 2

Active, not recruiting

Infantile SpasmsPhase 1

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Tricaprilin

CCerecin

Phase 3

1 2

Aimovig

Amgen

Preclinical

33 3

Emgality

Eli Lilly

Preclinical

19 4

Vyepti

Lundbeck

Preclinical

12 5

Savella

AbbVie

Preclinical

2 6

Bayer Aspirin

Bayer

Preclinical

2 7

Botox

RRevance Therapeutics, Inc.

Preclinical

9 8

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 9

Viagra

VViatris Specialty LLC

Preclinical

2 10

Pristiq

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Not yet recruiting

Alzheimer Disease

NCT05809908

Clinical

Trials by Indication[1]

Tics3 trials

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

Completed·CCerecin·Phase 1·NCT04268953·12 enrolled

Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production

Completed·CCerecin·Phase 1·NCT03551769·20 enrolled

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

Completed·CCerecin·Phase 1·NCT03971123·32 enrolled

Mild to Moderate Alzheimer's Disease1 trial

Tricaprilin in Mild to Moderate Alzheimer's Disease

Completed·CCerecin·Phase 2·NCT00142805·152 enrolled

Memory Impairment1 trial

Tricaprilin In Age-Associated Memory Impairment

Completed·CCerecin·Phase 2·NCT00355550·156 enrolled

Skin1 trial

Taste-masking Study for Tricaprilin in Sensory Panelists

Completed·CCerecin·Phase 1·NCT03628352·9 enrolled

Alzheimer's Disease1 trial

A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

Withdrawn·CCerecin·Phase 3·NCT04187547

3 more indications

Migraine1 trial

Tricaprilin Phase 2 Pilot Study in Migraine

Completed·CCerecin·Phase 2·NCT04437199·83 enrolled

Infantile Spasms1 trial

Tricaprilin Infantile Spasms Pilot Study

Completed·CCerecin·Phase 1·NCT04727970·8 enrolled

Alzheimer disease1 trial

A Phase 3, 26-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-OLE-01-VA in Participants With Mild to Moderate Alzheimer's Disease Dementia

Not yet recruiting·CCerecin·Phase 3·NCT05809908·535 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Tricaprilin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tricaprilin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tricaprilin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cerecin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCerecin

Tricaprilin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Tics3 trials

Mild to Moderate Alzheimer's Disease1 trial

Memory Impairment1 trial

Skin1 trial

Alzheimer's Disease1 trial

Migraine1 trial

Infantile Spasms1 trial

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News